Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
NCT07570654
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PTSD - Post Traumatic Stress Disorder
- PTSD
- PTSD Symptoms
- PTSD, Post Traumatic Stress Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- COMPASS Pathways
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- FL · Miami, FL
- FL · Orlando, FL
Illinois · 1
- IL · Chicago, IL
Minnesota · 1
- MN · Eden Prairie, MN
Nebraska · 1
- NE · Lincoln, NE
Nevada · 1
- NV · Las Vegas, NV
New York · 1
- NY · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.